

PMB definition guidelines for bipolar mood disorder

Version 1: 30.09.2020

Date published: 30 September 2020

Disclaimer:

The bipolar disorder benefit definition has been developed for the majority of standard patients. These benefits may not be sufficient for outlier patients. Therefore, regulation 15h and 15l may be applied for patients who are inadequately managed by the stated benefits.

Acknowledgements 1

The Council for Medical Schemes (CMS) would like to acknowledge all stakeholders who assisted in the drafting of this document, including the following general practitioners, psychiatrists, representatives from allied health professionals, patient advocacy groups, representatives from South African Medical Association (SAMA), pharmaceutical companies, different medical schemes and administrators:

Dr Kagisho Maaroganye (Psychiatrist) Dr Lauren Hill (Nutritionist) Dr Laurian Grace (Discovery Health) Dr Lindiwe Mbekeni (Discovery Health) Dr Mukesh Govind (General Practitioner) Dr Mvuyiso Talatala (Psychiatrist) Dr Natalie Benjamin (South African Society of Physiotherapy) Dr Nkokone Tema (Psychiatrist) Dr Sebolelo Seape (Psychiatrist) Dr Selaelo Mametja (SAMA) Mr Brian Fafudi (Psychological Society of South Africa) Ms Alta Kloppers (Association for Dietetics in South Africa) Ms Cassey Chambers (South African Depression and Anxiety Group) Ms Heidi Roth (South African Depression and Anxiety Group) Ms Magda Fourie (South African Society of Physiotherapy) Ms Menanda Hollands (Janssen) Ms Rosetta Masemola (Occupational Therapist) Ms Shelley Mc Gee (SAMA) Ms Tryphine Zulu (Medscheme) Prof Dana Niehaus (Psychiatrist) Professor Daleen Casteleijn (The Occupational Therapy Association of South Africa - OTASA) Professor Feroza Motara (Emergency Medicine - University of Witwatersrand)

In addition, the CMS would also like to acknowledge Dr Edith Madela-Mntla for her assistance in the writing of this document and Dr Gerhard Grobler who was consulted prior to publishing the draft document.

¹ All affiliations indicated were at the time of the stakeholder meeting held in February 2019.

Abbreviations

ALT APA	Alanine aminotransferase American Psychiatry Association
AST	Aspartate transaminase
BD	Bipolar Disorder
CMS	Council for Medical Schemes
СТ	Computed tomographic
DSM	Diagnostic and Statistical Manual
DTPs	Diagnosis Treatment Pairs
ECG	Electrocardiogram
EEG	Electroencephalogram
EUC	Electrolytes, urea and creatinine
GGT	Gamma glutamyl transferase
GP	General Practitioner
HDL	High-density lipoprotein
HIV	Human Immunodeficiency virus
ICD	International Classification of Diseases
IM	Intramuscular
ISBD	International Society for Bipolar Disorder
LDL	Low-density lipoprotein
MDD	Major Depressive Disorder
MRI	Magnetic resonance imaging
PMB	Prescribed minimum benefit
SADAG	South African Depression and Anxiety Support Group
SNRIs	Serotonin and Noradrenaline Reuptake Inhibitors
SSRIs	Selective Serotonin Reuptake Inhibitors
TCAs	Tricyclic antidepressants
Trig	Triglycerides
TSH	Thyroid stimulating hormone
U&E	Urea and electrolytes
UD	Unipolar Depression

Table of contents

1.	Introd	uction	.6
2.	Scope of Purpose		
3.	Defining Bipolar Disorder7		
4.	Class	ification of Bipolar mood disorder	. 8
5.	Epide	miology	. 9
6.	Como	orbidities and other associated factors for patients with bipolar mood disorder	.10
7.	Diagr	nosis of bipolar mood disorder	.10
	7.1	Differential diagnosis	. 10
	7.2	Criteria for diagnosis	. 11
	7.3	Diagnostic Basket	.14
		7.3.1 Consultations and disciplines for diagnosis	. 14
		7.3.2 Lab investigations for diagnosis	. 15
		7.3.3 Other investigations for diagnosis	. 16
8.	Mana	gement of bipolar mood disorder	.17
	8.1	Pharmacological management of bipolar mood disorder in and out-of-hospital	. 18
	8.2	Non-pharmacological management in and out-of-hospital	. 18
9.	Lab ir	nvestigations out-of-hospital	23
10.	Propo	osed recommendations to be considered for revised PMB package	.21
11.	Refer	ences	.27

Introduction

- 1.1. The legislation governing the provision of the prescribed minimum benefits (PMBs) is contained in the regulations enacted under the Medical Schemes Act, 1998 (Act No. 131 of 1998). In respect of some of the diagnosis treatment pairs (DTPs), medical scheme beneficiaries find it difficult to know their entitlements in advance. In addition, medical schemes interpret these benefits differently, resulting in a lack of uniformity of benefit entitlements.
- 1.2. The benefit definition project is coordinated by the CMS, with the aim to define the PMB package; and to guide the interpretation of the PMB provisions by relevant stakeholders. The guidelines are based on the available evidence of clinical and cost effectiveness, taking into consideration affordability constraints and financial viability of medical schemes in South Africa.

2. Scope and Purpose

- 2.1. This is a recommendation for the diagnosis, treatment and care of individuals with bipolar mood disorder in any clinically appropriate setting as outlined in the Medical Schemes Act.
- 2.2. The purpose of this guide is to improve clarity in respect of funding decisions by medical schemes, taking into consideration evidence-based medicine, affordability and in some instances, cost-effectiveness.

PMB	PMB Description	Treatment Component
Code		
902T	Major affective disorders, including unipolar and bipolar depression.	Hospital-based management up to 3 weeks/year (including inpatient electro-convulsive therapy and inpatient psychotherapy) or outpatient psychotherapy of up to 15 contacts.

Table 1: Applicable PMB code for bipolar mood disorder

Bipolar Mood Disorder is also included in the Chronic Disease List (CDL).

ICD10 code	WHO description
F31.0	Bipolar affective disorder, current episode hypomanic
F31.1	Bipolar affective disorder, current episode manic without psychotic symptoms
F31.2	Bipolar affective disorder, current episode manic with psychotic symptoms
F31.3	Bipolar affective disorder, current episode mild or moderate depression
F31.4	Bipolar affective disorder, current episode severe depression without psychotic symptoms
F31.5	Bipolar affective disorder, current episode severe depression with psychotic symptoms
F31.6	Bipolar affective disorder, current episode mixed
F31.7	Bipolar affective disorder, currently in remission
F31.8	Other bipolar affective disorders
F31.9	Bipolar affective disorder, unspecified

Table 2: Applicable ICD 10 codes for bipolar mood disorder

3. Defining bipolar disorder

- 3.1. Bipolar disorder (BD) is a brain disorder that causes changes in a person's mood, energy levels and ability to function. Bipolar disorder is characterised by episodes of mania, hypomania or depression. A person living with bipolar disorder will have severe mood swings which can last several weeks, months or a long period of time. The Royal College of Psychiatrists states that feelings include severe depression, feelings of extreme happiness or a combination of depression with restlessness (Scott et al., 2016).
- 3.2. A manic episode is an emotional state where a person is unusually irritable in an extreme way, most of the day for most days, has more energy than usual for at least one week. The change in mood is uncharacteristic of the person's usual state or behaviour. Changes in mood is severe enough to cause difficulties or impairment in the person's ability to function at work, with friends or family or other important areas in their life.

- 3.3. A hypomanic episode is similar to a manic episode; however, the symptoms are less severe and may only last four consecutive days.
- 3.4. A major depressive episode is a period of two weeks in which a person has at least five or more of the following symptoms: (Thakur, 2015; Scott et al., 2016);
 - Depressed mood, such as feeling sad, empty, hopeless or tearful
 - Loss of interest in activities
 - Feeling worthless or inappropriate guilt
 - Sleeping problems (Insomnia or sleeping too much)
 - Feeling restless or agitated or slowed behaviour
 - Changes in appetite
 - Loss of energy or fatigue
 - Difficulty concentrating, or indecisiveness
 - Frequent thoughts of death or suicide
- 3.5. Bipolar disorder is widely cited as one of the most severe psychiatric disorders and is among the most disabling and economically catastrophic medical disorders (Ayano, 2016). According to Ferrari et al (2016), despite being relatively rare, bipolar disorder is a disabling illness due to its early onset, severity and chronicity.
- 4. Classification of bipolar disorder

The most recent Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) classification recognises seven categories of bipolar disorder, namely: bipolar I disorder, bipolar II disorder, cyclothymic disorder, substance/medication induced bipolar and related disorder, bipolar and related disorder due to another medical condition, other specified bipolar and related disorder, and unspecified bipolar and related disorder (Jeste et al., 2013).

Bipolar I disorder is diagnosed when a person has had at least one manic episode that may be preceded or followed by hypomanic or major depressive episodes (SASOP, 2013).

Bipolar II disorder involves a person having at least one major depressive episode and at least one hypomanic episode, however, without a manic episode (SASOP, 2013).

Cyclothymic disorder is a milder form of bipolar disorder involving many mood swings, with hypomania and depressive symptoms that occur often and constantly but do not meet the criteria for major depressive disorder (SASOP, 2013).

5. Epidemiology

- 5.1. According to the Royal College of Psychiatrists (quoted in WPA, 2016), 1 in every 100 adults has bipolar disorder at some point in their life. The International Society for Bipolar Disorder (ISBD) works on a premise that the disease affects over 60 million people worldwide, a figure provided by the World Health Organisation (WHO) (2017). According to the Depression and Anxiety Support Group (SADAG, 2019), 3-4% of South Africans have Bipolar Disorder.
- 5.2. The South African Society of Psychiatrists reported the mean age of the first mood episode of bipolar 1 to be 18.2 years with a lifetime prevalence is 1%. For bipolar II disorder, the mean reported age of first mood episode is 20.3 years, while the lifetime prevalence is 1.1%. Bipolar I disorder affects men and women equally, while bipolar II disorder is more common in women (Emsley et al., 2013).
- 5.3. Bipolar disorder in children under 12 years is very rare (NICE,2014). For this reason, the NICE guideline recommends that the diagnosis of bipolar disorder in children or young people should be made only after a period of intensive, prospective longitudinal monitoring by a healthcare professional or multidisciplinary team trained and experienced in the assessment, diagnosis and management of bipolar disorder in children and young people, and in collaboration with the child or young person's parents or carers
- 5.4. Culpepper (2014) is of the view that age at onset appears to be decreasing, with the current median age at onset likely to be during the teenage years. Also, in the youth, manic and mixed states are more common, but, in adulthood, depression becomes more predominant. He further states that new-onset bipolar disorder is unusual in the elderly, so suspicion of this diagnosis in older patients should stimulate an investigation for a possible primary central nervous system disorder.
- 6. Comorbidities and other associated factors for patients with bipolar mood disorder
 - 6.1. In patients with bipolar disorder, comorbidity is the rule rather than the exception (Culpepper, 2010; Das, 2013). This was concluded from a US general population survey data which found that 100% of patients with bipolar I disorder reported at least 1 other psychiatric disorder in their lifetimes, and 95.5% reported 3 or more. From that study, anxiety disorders were present in 92.9% of patients with bipolar I disorder, 71.0%, in substance use disorders, 59.4% in conduct disorders and 29% in adult antisocial behaviours.
 - 6.2. According to Jann (2014), substantial challenges facing patients with bipolar disorder, in addition to their severe mood symptoms, include frequent incidence of psychiatric and general medical comorbidities. Common comorbities include anxiety disorders, alcohol or drug dependence (Culpepper, 2010), diabetes, cardiovascular disease, obesity, migraine, and hepatitis C virus infection. Both SASOP guidelines (Emsley et al. 2013) and the APA guidelines (Reus et al. 2017) corroborate the comorbid psychiatric disorders cited.

- 6.3. The risk of suicide is significantly higher among people with bipolar disorder than among the general population (Jeste et al. 2013). Bipolar disorder is almost always recurrent and can be associated with severe illness-related morbidity and increased medical mortality, with about 10 to 20 percent of patients with the condition dying of their illness by suicide (Ayano, 2016).
- 7. Diagnosis of bipolar mood disorder

Bipolar disorder diagnosis should be made over time as the full spectrum of the disorder does not present itself at one point in time (SASOP, 2013). According to Scott and Leboyer (2011), over 60% of individuals with bipolar disorders are reported to have received between 1-4 prior diagnoses, with delay in diagnosis being a problem in females with bipolar II disorders. This can be attributed to the fact that unipolar depression (UD) is more common than bipolar depression, and because bipolar depression lacks pathognomonic features, bipolar disorder is often incorrectly identified as major depressive disorder (MDD). Among patients who are eventually diagnosed with bipolar disorder, approximately 70% reportedly had an initial misdiagnosis and more than 33% remained misdiagnosed for 10 years or more (Jann, 2014).

- 7.1. Differential diagnosis
 - 7.1.1. Bipolar disorders must be differentiated from other psychiatric and medical illnesses, as well as from disorders such as heavy metal toxicity, adverse effects of drugs, and vitamin deficiencies (Jeste et al. 2013; Ayano, 2016). The NICE guidelines (2014) recommend considering the possibility of differential diagnoses, including schizophrenia spectrum disorders, personality disorders, drug misuse, alcohol-use disorders, attention deficit hyperactivity disorder and underlying physical disorders such as hypo/hyperthyroidism. The depressive manifestation in both unipolar and bipolar disorder is identical, however, the two require different psychopharmacological treatments. For this reason, it is beneficial to establish a diagnosis of bipolar depression prior to the expression of a manic episode (Heymann and Bonne, 2011).
 - 7.1.2. Differentiating bipolar disorder (BD) from recurrent unipolar depression (UD) is a major clinical challenge. Main reasons for this include the higher prevalence of depressive relative to hypo/manic symptoms during the course of BD illness, and the high prevalence of subthreshold manic symptoms in both BD and UD depression (NICE, 2014).
 - 7.1.3. Emsley et al. (2013) confirmed that separating major depressive disorder (MDD) and BD, particularly BD II, can be a challenge. This has reportedly been established from several reports that have found that BD is associated with:
 - A significantly earlier age of onset
 - More recurrences
 - Atypical and mixed depressions

- A family history of BD or completed suicide.
- 7.1.4. According to Ayano (2016) only one manic/hypomanic episode is required to diagnose bipolar rather than unipolar disorder.
- 7.2. Criteria for Diagnosis

Diagnostic categories and criteria for bipolar disorders show some concordance between the internationally and widely used Tenth Edition of the *International Statistical Classification of Diseases and Related Health Problems* (ICD-10) and the DSM 5 as they share many commonalities regarding diagnostic categorisation of bipolar and related disorders, and they both acknowledge the existence of a distinct bipolar disorder, which more or less represents a modern view of the classic manic-depressive disorder.

However, there are also major differences that are worth highlighting, as shown in tables below.

	ICD-10	DSM-5
Taxonomy	Bipolar disorders appear in the	Bipolar and related disorders are
	chapters of mood (affective)	summarised in a distinct chapter
	disorders, behavioural disorders	between "Schizophrenia
	due to psychoactive substance	Spectrum and Other Psychotic
	use, and organic mood	Disorders" and "Depressive
	(affective) disorder	Disorders."
Criteria for a manic episode	Mood must be Predominantly	Features of both elevated,
	elevated expansive, or irritable	Expansive or irritable mood AND
	for at least 1 week, plus at least	increased goal-directed- activity
	3 of 9 other symptoms are	or energy for at least 1 week
	required.	plus 3 or 7 other symptoms are
		required.
Single manic episode sufficient	No	Yes
for diagnosis of bipolar disorder		
Distinction between bipolar I and	Not explicitly	
bipolar II		Yes
Use of specifiers	No	Yes

Table 3: Difference between ICD-10 and DSM-5 regarding bipolar and related disorders

Mixed affective episode	Distinct diagnosis: Bipolar	Distinct specifiers: With mixed
	affective disorder, current	features.
	episode mixed.	
		This specifier is also applicable
		for patients with (unipolar) major
		depressive disorder.
Consideration of concurrent	No	Distinct specifier: With anxious
anxiety		distress
Date of release	1992	2013

Source: Kaltenboeck, Winkler, and Kasper (2016)

In terms of the differences, the following areas are worth pointing out: nosology, criteria for manic episodes and bipolar disorders, distinction of types of bipolar disorders, and the degree of details in categorization.

- Ø Nosologies used within the diagnostic systems: Both classifications discriminate between bipolar disorder and unipolar depression but represent this in different ways. However, none considers the occurrence of unipolar mania, which is seen as a major shortcoming in both systems, given the growing scientific evidence for the existence of unipolar mania.
- Ø Criteria for manic episode and bipolar disorders: DSM-5 has more restrictive criteria for a manic episode than ICD-10. This may have important implications for clinical practice and scientific investigation. This, according to Severus and Bauer (2013) might have the advantage of lowering the probability of false positive diagnoses and therefore help to avoid unnecessary psychopharmacological treatment. On the other hand, however, it leads to the problem that there might be patients who are diagnosed with mania or bipolar disorder in ICD-10 but must be allocated to a subthreshold group in DSM-5.
- Ø Distinction of types of bipolar disorders: DSM-5 allows for the diagnoses of bipolar I disorder and bipolar II disorder, while ICD-10 does not make such an explicit distinction. This appears to be a major shortcoming in the classification of bipolar disorders in ICD-10, as it does not take into account the spectrum of clinical symptomatology in patients with bipolar disorders. As a result, patients who present with their first episode of mood (affective) disorder can be diagnosed with a distinct category in ICD-10, such as (hypo)manic episode or depressive episode; DSM-5 does not make this distinction, meaning that a manic episode is sufficient to warrant a diagnosis of bipolar I disorder under this classification.
- Ø Details of a patient's clinical presentation: DSM-5 allows for the use of specifiers, which intends to allow better categorisation and easier communication among clinicians. ICD-10 takes into account some features that might be present in patients with bipolar disorders, such as psychosis or episodes with mixed features. However, this is far less extensive than the specifiers in DSM-5.

All the critiques of these classification systems pointed out that there are more than 20 years between the release of ICD-10 and DSM-5, and therefore some of the differences described might resolve when the new issue of the ICD (ICD-11) is published. An international survey of psychiatrists in 66 countries back in 2002, comparing use of the ICD-10 and DSM-IV, found that the former was more often used for clinical diagnosis while the latter was more valued for research (Mezzich, 2002). The ICD is the official system, although many mental health professionals do not realize this due to the dominance of the DSM.

The ICD-11 version for preparing implementation in Member States, including translations, was released on 18 June 2018 and accepted at the Seventy-second World Health Assembly for endorsement by Member States in May 2019. ICD-11 will come into effect on 1 January 2022 (WHO, 2019).

7.3. Diagnostic basket

The recommended PMB level of care diagnostic basket for bipolar disorder describes the professional disciplines that may make a diagnosis, as well as the investigations needed to make a definite diagnosis.

7.3.1. Consultations and disciplines for diagnosis

Many patients with bipolar disorder seek treatment in primary care practices, therefore, clinicians in these settings need to be able to diagnose bipolar disorder and common psychiatric and medical comorbidities; and to initiate and manage treatment (Culpepper, 2010).

According to the Mental Health Care Act No, 2002 (Act No. 17 of 2002), "a mental health practitioner" means a psychiatrist or registered medical practitioner or a nurse, occupational therapist, psychologist or social worker who has been trained to provide prescribed mental health care, treatment and rehabilitation services. A "mental health care provider" means a person providing mental health services to mental health care users and includes mental health practitioners (Mental health Act, 2002).

In view of the definitions of a mental health provider and / or practitioner, table 3 gives the recommended providers for diagnosis and the supportive allied providers.

Discipline	Comment	
General Practitioner	A GP can do the initial diagnosis and can initiate treatment. However, the patient should be referred to a psychiatrist within 6 months to confirm the diagnosis. Stable patients can be managed by the GP.	
Psychiatrist	Preferred provider for diagnosis	
Other supportive providers only upon referral from GP or psychiatrist		
Clinical psychologist		
Occupational therapist		

Table 4: Recommended disciplines for diagnosis of bipolar disorder

Social worker

According to Deckersbach (2010) two-thirds of patients with bipolar disorder experience a moderate to severe impact of the illness on occupational functioning. Occupational therapists (OT) work with these individuals to assist them in all capacities of their daily living. OT's can see not only to their mental well-being, but their physical well-being and safety (Covington, 2018). Through the application of different therapies, OTs can intervene in different occupational areas of life in people with mental disorders. The treatment produces more effect to drug treatments combined with cognitive or behavioural therapies (Rodríguez Martínez, M., & Montero Sánchez, R. (2017). In addition, Fast (2019), advises that Occupational therapy can be a great way to cope with bipolar disorder symptoms as it allows an individual to get their mind off negative thoughts and create something.

The National Alliance on Mental Illness asserts that Social workers help people overcome life's most difficult challenges; they help prevent crises and counsel individuals, families and communities to cope more effectively with the stresses of everyday life. Social workers focus on improving individual well-being in the context of family and other social structures, such as work and community (McLain, 2014).

7.3.2. Recommended baseline lab investigations for diagnostic workup

According to Soreff (2018), several reasons exist for obtaining selected laboratory studies in patients with bipolar disorder, or manic-depressive illness. An extensive range of tests is indicated, because bipolar disorder encompasses both depression and mania; also, because a significant number of medical causes for each state exists.

Table 5: Laboratory/ point of care baseline investigations for diagnostic work-up of bipolar disorder recommended as PMB level of care

Investigation		
Full blood count		
Urea and electrolytes including serum creatinine		
Fasting blood sugar and/ or random blood glucose		
Fasting lipogram		
• triglycerides,		
high-density lipoprotein (HDL),		
low-density lipoprotein (LDL)		
Thyroid stimulating hormone		

Trepone	ma pallidum hemagglutination	
HIV		
Liver fun	ction test	
•	Aspartate aminotransferase (AST)	
•	Alanine aminotransferase (ALT)	
•	Gamma glutamyl transferase (GGT)	
Toxic dru	ug screen	
Pregnan	cy test	
Vitamin B 12 - for patients above 60 years or when indicated		

7.3.3. Other baseline investigations for diagnostic work up of bipolar mood disorder


Table 6: Other investigations for diagnosis of bipolar disorder recommended as PMB level of car	re
(SASOP, 2013)	

Investigation	Comment
24-hour EEG	Only if there is any clinical suspicion of temporary lobe epilepsy
Computed tomography (CT)	Clinically indicated for 1 st episode patients and ALL late onset
Brain MRI	Only on motivation as CT is usually adequate
ECG with QTc calculation	Baseline ECG should be performed as most medication prolongs the QT interval.

8. Management of bipolar mood disorder

There is currently no cure for bipolar disorder, but treatment can help control symptoms (NIMH, 2015). People with bipolar disorder can be adequately managed and subsequently lead a very full and productive life (Scott et al. 2016).

Figure 1: Treatment algorithm for bipolar mood disorder as outlined in the Medical Schemes Act Chronic Disease List



Bipolar mood disorder Algorithm


8.1. Pharmacological management of bipolar disorder in and out-of-hospital

The CMS reviewed international and local guidelines; a phase-based treatment of bipolar disorder, as indicated in figure 4 is recommended (Emsley et al. 2013). The CMS recommends that medical management out-of-hospital (maintenance phase) should be a continuation of medicines already initiated in-hospital, except for medicines used for agitation. The

selection of maintenance medicines should be on an individual basis, taking into consideration efficacy and tolerability profiles. In addition, consideration needs to be given to individual patient factors (preference, past response, safety).



Figure 2: Phases of bipolar illness with matching treatment terminology (Emsley et al. 2013)



The above approach mainly recommends the use of the following agents:

- Anti-manic agent
- Bipolar depression agent
- Maintenance agent

8.1.1. <u>Anti-manic agents</u>

- 8.1.1.1. Anti-manic agents include anticonvulsants (e.g. sodium valproate, carbamazepine and lamotrigine), lithium and antipsychotics.
- 8.1.1.2. Based on randomised clinical trials, lithium occupies a particularly important role in the prevention of relapse to mania and depression. Valproate and lithium are used in the manic episode as monotherapy or in combination with atypical antipsychotics. Valproate should be used with extreme caution in women of childbearing age due to the risk of foetal malformations and adverse neurodevelopmental outcomes after any exposure in pregnancy (NICE, 2014). Lamotrigine is used in the maintenance mainly for the prevention of depressive episodes (SASOP, 2013). There is no consensus of the role of carbamazepine, it is however listed as a second line maintenance agent in the SASOP guidelines (SASOP, 2013).
- 8.1.1.3. Antipsychotics are classified as typical (first generation antipsychotics) or atypical (second generation antipsychotics). Atypical antipsychotics are the newer drugs which are generally well tolerated with less side effects when compared to the older drugs. Medicines in this class are recommended as 1st line agents.
- 8.1.1.4. Typical antipsychotics are the older drugs with generally more serious side effects and are recommended as 2nd line agents.

8.1.2. Bipolar depression agent

- 8.1.2.1. Lamotrigine, valproate and lithium are also recommended in the depressive phase of bipolar mood disorder.
- 8.1.2.2. Atypical antipsychotics, e.g. quetiapine and olanzapine are recommended as PMB level of care.
- 8.1.2.3. Antidepressants are the most commonly prescribed drug class for treating depression. The benefits of conventional antidepressants such as the tricyclic antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs), and serotonin and noradrenaline reuptake inhibitors (SNRIs) in the treatment of bipolar depression is currently unclear. If a conventional antidepressant is employed for bipolar depression, it should be concurrently administered with an anti-manic maintenance agent to diminish the possibility of switching (SASOP, 2013). SSRIs (e.g. fluoxetine, citalopram, escitalopram) are recommended as 1st line antidepressants in combination with mood stabilisers.

8.1.3. <u>Maintenance therapy</u>

8.1.3.1. There is limited evidence for combining treatments hence monotherapy is preferred.

Table 7: Summary of therapeutic classes and examples of medicines recommended as PMB level of care for bipolar depression²

Medicine class	Examples of medicines		
Manic/ hypomanic episode			
	Lithium carbonate		
	Anticonvulsants		
Mood stabilisers	 Sodium valproate (PO and IMI) Carbamazepine Lamotrigine 		
Second generation antipsychotics/ Atypical antipsychotics	 Quetiapine Olanzapine (PO and IMI) Risperidone Aripiprazole³ 		
First generation antipsychotics/ Typical antipsychotics	 Haloperidol – when other options have failed as it lacks efficacy in maintenance treatment 		
Depressive episode	Depressive episode		

²Schemes can develop their own formularies which should include medicines from all classes recommended ³ Indicated for children and for cardiovascular unstable patients.

Mood stabilisers	 Lithium carbonate Sodium valproate Lamotrigine 			
Atypical antipsychotics	QuetiapineOlanzapine			
Typical antipsychotics	Not recommended for depression phase			
Antidepressants (only in combination with mood stabilisers)	 Ø SSRI's (1st line) Fluoxetine Citalopram Ø Norepinephrine- Dopamine Reuptake Inhibitors (2nd line) Bupropion Ø SNRIs are not recommended 			
Agitation in mania and/ or depression	on			
	 Lorazepam IM Olanzapine IM Ziprasidone IMI⁴ Haloperidol Zuclopenthixol Clonazepam IMI Clothiapine IMI 			
Maintenance				
Mood stabilisers	 Lithium carbonate - mainly for preventing manic episodes Lamotrigine- mainly for preventing depressive episodes Sodium valproate Carbamazepine – 2nd line 			
Atypical antipsychotics	 Quetiapine Olanzapine Risperidone Aripiprazole 			

8.2 Non-pharmacological management in and out-of-hospital

8.2.1. Ayano (2016) and Goodwin et al (2016) agree that the complexity of bipolar disorders usually renders any single therapeutic approach inadequate to deal with the multifaceted disorder, and therefore psychosocial modalities, including psychoeducation and behaviour change, should be integrated into the drug treatment regimen. Adjunctive psychosocial therapies should also be considered early in the course of illness to improve medication adherence, identify prodromes of relapse, decrease residual symptoms

⁴ For sedation

(particularly depressive) and suicidal behaviour, and help move patients towards a comprehensive functional recovery.

- 8.2.2. There is strong evidence for non-pharmacological management to compliment pharmacotherapy in the holistic management of bipolar disorder (Scott et al., 2016; Jeste et al., 2013; NICE, 2014). These interventions should include the entire multidisciplinary team. In psychotherapy, the individual works alongside a mental health professional to decide a treatment plan, better understand the illness and to help rebuild relationships. Helping the person cope with the stress of the illness, especially as it affects relationships and ability to work, is often very important. According to Connolly and Thase (2011) psychoeducation focusing on recognition of early warning signs of relapse is an effective adjunct to medication management and should be offered to all patients with bipolar disorder. More intensive psychotherapies (cognitive-behavioural therapy, family focused therapy, interpersonal and social rhythm therapy) have also demonstrated benefit as adjuncts to improve both symptoms and function and should be considered.
- 8.2.3. The current Medical Schemes Act stipulates 15 psychotherapy sessions out hospital. The CMS recommends that a care plan should be submitted to the funder/ administrator when a patient is diagnosed with bipolar mood disorder. The case coordinator will be able to assist and ensure the optimal utilisation of the 15 sessions currently prescribed. Patients should also get appropriate referral from the treating doctor to the most appropriate allied health professional. It is also important that all benefits especially for allied health professionals are individualised and not bundled as family benefits. The social workers and psychologists are recommended for patients with bipolar mood disorder when referred by the treating provider.
- 8.2.4. Other allied healthcare professionals who may play a role in selected patients when clinically indicated include occupational therapists, physiotherapists and dieticians.
- 8.2.5. Follow-up consultations are included in the PMB level of care under the "care" component for bipolar mood disorder and may not form part of the 15 psychotherapy sessions.
- 9. Lab investigations out-of-hospital

Maintenance of euthymia is the primary goal in the long-term treatment of bipolar disorder and is best achieved using long-term medication (Conolly and Thase, 2011). The long-term use of some of the medication warrants ongoing monitoring of the patient. The table below provides guidance on the drugs which need to be monitored.

Table 8: Recommended drug specific laboratory investigations

Patient Is	Check	Monitor for:
Maintained on:		
Lithium	Drug serum level: once therapeutic level is achieved, every 3–6 months	Sub-therapeutic or toxic level
	Electrolytes, urea and creatinine (EUC): every 3–6 months	Renal insufficiency, nephrogenic diabetes insipidus
	Calcium, TSH, weight: after 6 months and then annually	Thyroid/parathyroid dysfunction
Valproate	Serum level: during initial therapy and then as clinically indicated	Sub therapeutic or toxic level
	Weight, complete blood count, menstrual history, liver function tests every 3 months for the first year and then annually	Weight gain, thrombocytopenia, dysmenorrhea, liver failure
	Blood pressure, fasting blood glucose, lipid profile, bone densitometry (if risk factors)	Metabolic syndrome, anticonvulsant-related osteopenia
Carbamazepine	Serum level: during initial therapy and then as clinically indicated	Sub therapeutic or toxic level
	Complete blood count, liver function tests, EUC monthly for 3 months then annually Bone densitometry	Blood dyscrasias, liver failure, hyponatremia, monitor for rash, anticonvulsant- related osteopenia, Stevens-Johnson Syndrome
Lamotrigine		Stevens-Johnson Syndrome Monitor for rash
Second-generation antipsychotics	Weight monthly for 3 months and then every 3 months	Weight gain
	Blood pressure, fasting blood glucose, lipid profile every 3 months and then annually	Metabolic syndrome
	Abnormal movements	Acute dystonias, drug-induced parkinsonism, tardive dyskinesia
	Electrocardiogram, prolactin as clinically indicated	QTc prolongation/dysrhythmias, hyperprolactinemia

Table 9: Other lab investigations recommended as PMB level of care out-of-hospital
--

Investigation	Frequency	Comment
Glucose	Twice yearly and thereafter annually	Co-morbid diabetes may be exacerbated by antipsychotic medication hence medical monitoring is advocated in addition to education about lifestyle modification (Owen, Sawa & Mortensen, 2016; De Hert et al., 2011).
Lipogram	Annually	All individuals with bipolar disorder should be under active care and be screened for cardiometabolic risk at least annually if they have normal baseline values. Those who already present with cardiovascular risk factors should be monitored more frequently (Owen, Sawa & Mortensen, 2016; De Hert et al., 2011).
AST, ALT and GGT	Annually	Asymptomatic increases in ALT, AST, GGT and serum bilirubin levels in the first month of the study. These results were in accordance with previous studies that asymptomatic increase of liver enzymes are common but significant liver enzyme elevations are rare during atypical antipsychotic treatment. We suggest that obtaining baseline liver enzyme tests before atypical antipsychotic therapy and monitoring regularly specifically in patients with risk factors for liver damage during therapy (Atasoy et al., 2007).
Prolactin	Annually	Antipsychotic-induced hyperprolactinaemia has been estimated to occur in up to 70% of patients with bipolar disorder depending on the choice of antipsychotic agent (Barnes & Paton, 2011).

11. References

American Psychiatric Association., 2017. What are bipolar disorders? Available at <u>https://www.psychiatry.org/patients-families/bipolar-disorders/what-are-bipolar-disorders</u>. Accessed on 17 February 2019.

Ayano, G., 2016. Schizophrenia: a concise over view on etiology epidemiology diagnosis and management: review on literature. *J Schizophrenia Res*, *3*(2), pp.2-7.

Connolly, K.R. and Thase, M.E., 2011. The clinical management of bipolar disorder: a review of evidence based guidelines. *The primary care companion for CNS disorders*, *13*(4).

Covington, FB, 2018. Bipolar Disorder: OT Review and Study Guide. The International Institute for Therapeutic Intervention and Learning. Available at https://occupationaltherapyinsights.libsyn.com/bipolar-disorder-ot-review-and-study-guide

Culpepper, L., 2010. The role of primary care clinicians in diagnosing and treating bipolar disorder. *Primary care companion to the Journal of clinical psychiatry*, *12*(Suppl 1), p.4.

Culpepper, L., 2014. The diagnosis and treatment of bipolar disorder: decision-making in primary care. *The primary care companion for CNS disorders*, *16*(3).

Das, A., 2013. Anxiety disorders in bipolar I mania: prevalence, effect on illness severity, and treatment implications. *Indian journal of psychological medicine*, *35*(1), p.53.

Deckersbach T, Nierenberg AA, Kessler R, Lund HG, Ametrano RM, Sachs G, Rauch SL, Dougherty D. (2010) RESEARCH: cognitive rehabilitation for bipolar disorder: an open trial for employed patients with residual depressive symptoms. CNS Neurosci Ther 16:298–307.

Emsley, R., Hawkridge, S., Potocnik, F.C., Seedat, S., Flisher, A.J., Stein, D.J., Grobler, G., Swingler, D. and Szabo, C.P., 2013. Introduction: The South African Society of Psychiatrists (SASOP) Treatment Guidelines for Psychiatric Disorders. *South African Journal of Psychiatry*, *19*(3), pp.134-135.

Fast, J. 2019. Occupational Therapy: Let Your Mind Rest & Reduce Your Symptoms. Bphope- hope & harmony for people with bipolar. https://www.bphope.com/bipolar-stories-video-blog/video-how-to-allow-your-hands-to-take-over-for-your-mind/

Goodwin, G.M., Haddad, P.M., Ferrier, I.N., Aronson, J.K., Barnes, T.R.H., Cipriani, A., Coghill, D.R., Fazel, S., Geddes, J.R., Grunze, H. and Holmes, E.A., 2016. Evidence-based guidelines for treating bipolar disorder: Revised

third edition recommendations from the British Association for Psychopharmacology. *Journal of Psychopharmacology*, *30*(6), pp.495-553.

Heymann, S. and Bonne, O., 2011. Comparison between unipolar and bipolar depression: review of functional neuroimaging studies. *Harefuah*, *150*(10), pp.782-7.

Jann, M.W., 2014. Diagnosis and treatment of bipolar disorders in adults: a review of the evidence on pharmacologic treatments. *American health & drug benefits*, 7(9), p.489.

Jeste, D.V., Savla, G.N., Thompson, W.K., Vahia, I.V., Glorioso, D.K., Martin, A.V.S., Palmer, B.W., Rock, D., Golshan, S., Kraemer, H.C. and Depp, C.A., 2013. Association between older age and more successful aging: critical role of resilience and depression. *American Journal of Psychiatry*, *170*(2), pp.188-196.

Kaltenboeck, A; Winkler, D and Kasper, S (2016). Bipolar and related disorders in DSM-5 and ICD-10. CNS Spectrums (2016), 21, 318–323. © Cambridge University Press 2016

Konecky, B., Meyer, E.C., Kimbrel, N.A. and Morissette, S.B., 2016. The structure of DSM-5 posttraumatic stress disorder symptoms in war veterans. *Anxiety, Stress, & Coping, 29*(5), pp.497-506.

Malhi, G.S., Bassett, D., Boyce, P., Bryant, R., Fitzgerald, P.B., Fritz, K., Hopwood, M., Lyndon, B., Mulder, R., Murray, G. and Porter, R., 2015. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders. *Australian & New Zealand Journal of Psychiatry*, *49*(12), pp.10871206.

McLain 2014. Recognizing the Important Role of Social Workers. National Alliance on Mental Illness. https://www.nami.org/About-NAMI/NAMI-News/2014/Recognizing-the-Important-Role-of-Social-Workers

Mental health act No. 17 of 2002. Available at <u>https://www.gov.za/sites/default/files/gcis_document/201409/a17-02.pdf</u> Accessed on 12 March 2019.

Mezzich, JE. 2002. <u>"International Surveys on the Use of ICD-10 and Related Diagnostic Systems"</u> (guest editorial, abstract). *Psychopathology*. 35 (2–3): 72–75.

NICE, 2014. Bipolar disorder: assessment and management Clinical guideline. *Published: 24 September 2014. nice.org.uk/guidance/cg185*

Phillips, M. L., & Kupfer, D. J. 2013. Bipolar disorder diagnosis: challenges and future directions. *Lancet (London, England)*, *381*(9878), 1663-71.

Reed, GM. 2010. Toward ICD-11: Improving the clinical utility of WHO's International Classification of mental disorders. *Professional Psychology: Research and Practice*. 41 (6): 457–464.

Reed et al, 2019. Innovations and Changes in the ICD-11 classification of mental, behavioural and neurodevelopmental disorders. World Psychiatry, Volume 18 issue 1.

Reus, V.I., Fochtmann, L.J., Bukstein, O., Eyler, A.E., Hilty, D.M., Horvitz-Lennon, M., Mahoney, J., Pasic, J., Weaver, M., Wills, C.D. and McIntyre, J., 2017. The American Psychiatric Association practice guideline for the pharmacological treatment of patients with alcohol use disorder. *American Journal of Psychiatry*, *175*(1), pp.86-90.

Rodríguez Martínez, M., & Montero Sánchez, R. (2017). Occupational therapy in bipolar disorder. *Revista Chilena de Terapia Ocupacional, 17*(1), 91-104. doi:10.5354/0719-5346.2017.46381

Royal College of Psychiatry. (2015). Available at <u>https://www.rcpsych.ac.uk/mental-health/treatments-</u> andwellbeing/antipsychotics. Accessed on 23 February 2019.

Scott, J. and Leboyer, M., 2011. Consequences of delayed diagnosis of bipolar disorders. *L'Encéphale*, *37*, pp.S173-S175.

Scott, K.M., Lim, C., Al-Hamzawi, A., Alonso, J., Bruffaerts, R., Caldas-de-Almeida, J.M., Florescu, S., De Girolamo, G., Hu, C., De Jonge, P. and Kawakami, N., 2016. Association of mental disorders with subsequent chronic physical conditions: world mental health surveys from 17 countries. *JAMA psychiatry*, *73*(2), pp.150-158.

Severus E, Bauer M. 2013. Diagnosing bipolar disorders in DSM-5. Int J of Bipolar Disord. 2013; 1:14.

Thakur, M.E. ed., 2015. *The American psychiatric publishing textbook of geriatric psychiatry*. American Psychiatric Pub.

Tobias A. Rowland and Steven Marwaha., 2018. Epidemiology and risk factors for bipolar disorder. *The Adv Psychopharmacol.*